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Purpose: Deformable image registration (DIR) plays an important role in dose accumulation, such as
incorporating breathing motion into the accumulation of the delivered dose based on daily 4DCBCT
images. However, it is not yet well understood how the uncertainties associated with DIR methods
affect the dose calculations and resulting clinical metrics. The purpose of this study is to evaluate the
impact of DIR uncertainty on the clinical metrics derived from its use in dose accumulation.
Methods: A biomechanical model based DIR method and a biomechanical-intensity-based hybrid
method, which reduced the average registration error by 1.6 mm, were applied to ten lung cancer
patients. A clinically relevant dose parameter [minimum dose to 0.5 cm3 (Dmin)] was calculated for
three dose scenarios using both algorithms. Dose scenarios included static (no breathing motion),
predicted (breathing motion at the time of planning), and total accumulated (interfraction breathing
motion). The relationship between the dose parameter and a combination of DIR uncertainty metrics,
tumor volume, and dose heterogeneity of the plan was investigated.
Results: Depending on the dose heterogeneity, tumor volume, and DIR uncertainty, in over 50% of
the patients, differences greater than 1.0 Gy were observed in the Dmin of the tumor in the static dose
calculation on exhale phase of the 4DCT. Such differences were due to the errors in propagating the
tumor contours from the reference planning 4DCT phase onto a subsequent 4DCT phase using each
DIR algorithm and calculating the dose on that phase. The differences in predicted dose were more
subtle when breathing motion was modeled explicitly at the time of planning with only one patient
exhibiting a greater than 1.0 Gy difference in Dmin. Dmin differences of up to 2.5 Gy were found
in the total accumulated delivered dose due to difference in quantifying the interfraction variations.
Such dose uncertainties could potentially be clinically significant.
Conclusions: Reductions in average uncertainty in DIR algorithms by 1.6 mm may have
a clinically significant impact on the decision-making metrics used in dose planning and
dose accumulation assessment. C 2016 American Association of Physicists in Medicine.
[http://dx.doi.org/10.1118/1.4938412]
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1. INTRODUCTION
Stereotactic body radiation therapy (SBRT) is an effective
treatment option in various anatomical sites. However, due
to the high dose per fraction in SBRT, even small geometric
uncertainties in defining and targeting the anatomy on the
planning and treatment delivery images could potentially
reduce the therapeutic ratio and increase the risk of normal tis-
sue toxicity.1 Geometric uncertainties, patient setup, breathing
motions, tumor response, and radiation-induced edema may
lead to changes which compromise the delivery of the planned
dose.2,3 Therefore, it is important to understand and quantify
the uncertainties in the delivered dose in SBRT patients by
accurate accumulation of dose over the course of treatment.1,4
Cone-beam computed tomography (CBCT), as one of the
available medical imaging technologies, has been extensively
used in image-guided radiotherapy (IGRT).5 CBCT has shown
daily changes in the anatomy that rigid alignment cannot
correct. Deformable image registration (DIR) determines the
voxel to voxel correspondence between different images,
enabling the propagation of planning contours and the
accumulation of the delivered dose. Dose accumulation,
summing the dose delivered to the same voxel of tissue
tracked over the course of treatment through DIR, can help us
understand how these uncorrected errors affect the deviation of
the delivered dose compared to the planned dose distribution.
Although several studies have reported on retrospective
dose accumulation in the lung,6–8 it has not translated
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into prospective clinical trials and widespread use. This
is due in part to limitations in the implementation of the
process into clinical workflow, but also due to the lack of
a clear understanding of how the uncertainties associated
with DIR algorithms impact the applications of the DIR
especially in SBRT.9 Previous studies showed that intensity-
based DIR algorithms can be erroneous in homogeneous
regions of images.10 However, through the use of inverse
consistency (IC), intensity-based DIRs can improve dose
accumulation results.11,12 These studies highlight the need
to relate clinical decision parameters (e.g., minimum dose
to the target and maximum dose to the normal tissue) to
the uncertainty in DIR algorithms on dose accumulation
results.
The purpose of this work is to quantify the impact of
DIR uncertainty on the clinical parameters calculated from
DIR-based dose accumulation. To illustrate the concept,
, a biomechanical model based DIR, and a newly
developed Hybrid version, which combines a limited scope
intensity-based DIR in series with  leading to a
reduction in the uncertainty of 1.6 mm on average,13 will
be used to perform dose accumulation in lung SBRT
patients. The results of this work show its potential to be
used for further quantification of the relationship between
geometric and dosimetric uncertainties in DIR-based dose
accumulation.
2. METHODS AND MATERIALS
Ten nonsmall cell lung cancer (NSCLC) patients
previously treated with SBRT over 3 or 4 fractions were used
for this retrospective analysis. Each patient was previously
planned for SBRT with the gross tumor volume (GTV) and
dose calculations performed on the end exhale phase of 4DCT
using an internal target volume (ITV) constructed from the
breathing motion observed on the 4DCT and a planning target
volume (PTV) margin of 5 mm. All the patients were treated
with 6 MV energy using 3D conformal delivery technique and
IGRT by 4DCBCT. 4DCBCT scans with ten breathing phases
were acquired for each fraction just prior to the delivery of
the treatment. For all patients with (*) sign in their number
of beams in Table I, a subset of beams were non-coplanar.
The prescribed dose ranged from 48 to 60 Gy, as shown
in Table I. V20 was defined as the percent of the lungs’
volumes excluding the GTV that received greater than 20
Gy. Two patients (9 and 10) had each two GTVs treated
with two separate plans. Dose heterogeneity index (DHI)
proposed by Ding et al.14 was used to determine the level of
inhomogeneity of the plan within the PTV. The 4DCT and
4DCBCT had the same voxel size of 0.9×0.9×2.5 mm3.
In some cases for 4DCBCT, the resolution was slightly
higher with 0.8×0.8×2.0 mm3. The inhale and exhale dose
grids which were imported from the treatment planning
system (TPS) ( v9.2, Philips Medical Systems,
Madison, WI) had a voxel size of 2.5× 2.5× 2.5 mm3,
which was larger than those of the 4DCT and 4DCBCT
images.
T I. Planning information.
Patient No. No. of beams Prescription Location V20 DHI
1 9* 60 Gy/3 RL 3.5 14.2
2 7* 54 Gy/3 LLL 7 17.4
3 9* 60 Gy/3 LL 7.8 27.5
4 9* 48 Gy/4 RL 2.6 13.0
5 9* 48 Gy/4 RL 2.4 10.6
6 9* 48 Gy/4 RL 1.3 19.9
7 9* 60 Gy/3 RLL 7.9 21.4
8 9* 54 Gy/3 LL 5 18.5
9,1 10* 48 Gy/4 RUL 2.0 19.6
9,2 9* 48 Gy/4 RLL 2.0 16.7
10,1 9* 48 Gy/4 LLL 11.2 23.3
10,2 9* 48 Gy/4 RUL 11.2 11.8
Average N/A N/A N/A 5.3 17.8
Note: RL, right lung; LL, left lung; LLL, left lower lobe; RLL, right lower lobe;
and RUL, right upper lobe.
2.A. Modeling and deformable image registration
For each patient, 3D tetrahedral models of the lungs,
body, and the GTV(s) were created from contours on the
end-inspiration 4DCT in the TPS, as previously described.13
Additional normal tissues, including esophagus, trachea,
central bronchus, and heart were also modeled by assigning
appropriate material properties to subsets of body tetrahedrons
(using their imported contours from TPS to classify the
tetrahedrons to the tissue).
To model the breathing motion defined by the 4DCT,
the inhale 4DCT image was deformed to the exhale 4DCT
(predicted dose, Fig. 1). To model the interfraction motion
of patient over the course of treatment and the intrafraction
breathing motion at the time of treatment, the inhale 4DCT
image was deformed to the inhale 4DCBCT at the treatment
fraction and then to the exhale 4DCBCT image (accumulated
dose, Fig. 1). Both, a biomechanical model based DIR
and a recently developed Hybrid technique, which combines
 with an intensity-based registration algorithm, were
used to model the breathing motion as well as interfraction
motions. In , a guided surface projection algorithm
(, Altair Engineering, Troy, MI) was used to
determine the boundary conditions by comparing the surface
of primary and secondary lung finite element method (FEM)
models. Linear elastic material properties were assigned to
each organ creating a heterogeneous multiorgan model.15
The deformations were then determined by solving for
displacements of internal nodes using commercial physics
solver software (, ABAQUS, Inc, Pawtucket, RI).
The second DIR algorithm, the Hybrid method, was
performed by refining the deformations obtained by 
through a B-spline based intensity-based registration (Drop,
Munich, Germany).16 In the hybrid process, it was ensured
that the refinement step produces small magnitude differences
with a guaranteed positive Jacobian resulting in an overall
biomechanically plausible estimation of the ground truth
deformations. The Hybrid method reduces the local residual
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F. 1. Schematic overview of the dose scenario calculations using DIR. In the static dose, the DIR-warped contour from inhale to exhale is used to calculate
Dmin based on the exhale dose grid. In the predicted dose, both inhale and exhale grids (imported from TPS) together with the DIR deformation vector field
(DVF) are used in a breathing model to cumulate the dose in six weighted steps to include variant contribution of each of the dose grids in the breathing dose.
The accumulated dose is the sum of each fraction’s (denoted by FXi in the figure) breathing doses. For each fraction, the inhale CT is first registered to inhale
CBCT to account for setup and interfraction motions. Next, the inhale CBCT is registered to exhale CBCT to provide the DVF for the breathing model. The
total accumulated dose is the sum of all fractions. The number of fractions is 3 or 4 depending on the patient’s plan. In all three dose experiments, two sets of
results are obtained by separate application of  and the Hybrid DIR method.
uncertainties in  results as demonstrated in Ref. 13
and confirmed in Sec. 3.A.
2.B. Model validation
Target registration error (TRE) was used to evaluate
the uncertainty of the deformable registration. TRE was
calculated based on the Euclidean distance of corresponding
anatomical points selected on the inhale and exhale planning
CT images. A minimum of 29 (average of 33) points per lung
per patient were selected by an expert. Effort was made to
select the points with the highest possible spatial dispersion
throughout the lung regions. The intraobserver variability was
calculated by having the same expert (MV) reselect the points
on the exhale CT when shown the points on the inhale CT.
The GTV contour manually drawn on the inhale CT was
mapped onto the exhale CT using both  and Hybrid.
The Dice similarity coefficient (DSC) was computed between
the mapped GTV and the manually drawn GTV on the exhale
CT. In addition to DSC, the difference in the center of gravity
(COG) of the tumor on the inhale and exhale CT was measured
and compared to the COG shift calculated from  and
Hybrid.
Quantification of the DIR uncertainty (using both 
and Hybrid) was also performed using the DSC and the
surface distance (based on Hausdorff distance) values obtained
for each registration step in each fraction. The GTVs were
contoured on each pair (inhale and exhale) of the 4DCBCT
images from each fraction. The GTV contours mapped from
the inhale CT onto each 4DCBCT using the DIR and the
manually drawn GTV contours on the each 4DCBCT image
were used to calculate the DSC and the surface distance values
for each patient’s tumor over the entire treatment course.
2.C. Static, predicted, and accumulated dose
Figure 1 illustrates the three different dose terminologies
in this paper, static, predicted, and accumulated dose, using
a schematic of how they are calculated. The experiments
were designed to build on each previous step, as outlined in
Fig. 1.
Static dose refers to the clinical plan on the exhale phase of
the 4DCT, which accounts for the breathing motion through
the use of an asymmetric PTV margin, but does not account
for the normal tissue motion in and out of the PTV during
breathing motion. In the static dose case, the uncertainty
in DIR impacts the mapping of the GTV contour from the
inhale CT to the exhale CT and the quantification of the dose
delivered to the warped GTV when the GTV is in the exhale
breathing position only (i.e., there is no dose accumulation
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in this initial step). As shown in Fig. 1, static dose, different
dose values can be obtained with different warped GTVs
from inhale to exhale position using each DIR algorithm.
Thus, the entire reported dose in the static dose case is
influenced by the DIR uncertainty. Here, comparisons can
also be made to the actual GTV position as visualized and
contoured on the exhale 4DCT image and the dose calculated
to the known GTV location (static dose, Fig. 1). This level
of gold standard is not possible for the following two experi-
ments.
The predicted dose (Fig. 1) calculates an estimate of
the delivered dose based on the breathing motion observed
on the 4DCT obtained at the time of treatment planning.
The accumulation is performed based on DIR results and a
previously published periodic asymmetric probability density
function method to model the breathing motion between
inhale and exhale states.17 For each tetrahedral element, dose
is determined based on the relative time weights reflecting the
asymmetry of the breathing cycle.18 This dose represents an
estimate of the dose that would be delivered assuming perfect
daily image guidance and consistent breathing motion from
4DCT at each fraction. The dose for each tetrahedral element
is the summed in six breathing increments from the inhale to
the exhale state. In the predicted dose case, the uncertainty
in the DIR impacts the mapping of the GTV contour onto
the inhale image as well as the accumulated dose, which
is determined from tracking the tissue between CT images
based on the DIR. Since the dose is calculated over a breathing
cycle rather than just one extreme phase (as it is computed in
the static dose), the impact of DIR-based uncertainties on the
clinical metrics is expected to be less in the predicted dose case
than in the static dose case. Because, the largest dose changes
occur at the extreme exhale phase where DIR uncertainties
are largest. However, in the predicted dose, whereby the dose
is summed in six weighted increments including the exhale
step, the exhale dose has limited contribution in the overall
dose.
The accumulated dose (Fig. 1) calculates the dose delivered
based on the 4DCBCT obtained at the start of each treatment
fraction. This accounts for unresolved anatomical differences
between the reference position at treatment planning and the
corresponding reference position at each fraction of treatment
delivery (3 or 4 treatment fractions), as well as variations in
the breathing motion determined from the 4DCBCT. For each
treatment fraction, DIR-based dose accumulation (using both
 and the Hybrid DIR algorithm) was performed using
the exhale 4DCBCT and the inhale 4DCBCT to account for
residual setup uncertainties, changes in the patient position,
and the breathing motion observed just prior to the delivery
of the treatment fraction. The dose accumulation is the
summation of the breathing dose over all fractions. The
breathing dose in each fraction is calculated in a process
similar to the predicted dose but based on deformation vectors
mapping inhale CBCT to exhale CBCT. In the accumulated
dose case, the uncertainty in the DIR impacts the mapping of
the GTV contour onto the exhale and inhale CBCT images as
well as the accumulated dose between exhale and inhale and
across all fractions.
2.D. Dose accumulation parameters
A standard method of reporting the dose to the tumor is
the use of the minimum dose to a small (less than 0.5 cm3)
volume of the tumor.19 Therefore, the sensitivity of this
parameter, minimum dose to 0.5 cm3 of the tumor (denoted
as Dmin), was used to quantify the impact of the uncertainty
in DIR-based dose accumulation. Dmin was calculated for
the static dose, predicted dose, and accumulated dose using
 and Hybrid to determine the sensitivity of the Dmin
parameter on the DIR uncertainty.
Wilcoxon signed rank test was used to determine whether
the difference in Dmin results obtained using each of the DIR
algorithms was statistically significant. Wilcoxon signed rank
test is especially useful for Dmin in this study since the normal
distribution assumption regarding the Dmin data could not be
made. A similar test was performed for the TRE validation,
COG mapping, and DSC values to determine the statistical
significance. Linear regression model was used to test the
statistical relationship between planning and geometric error
parameters and various Dmin. Adjusted R2 value was obtained
for the overall regression, and p-values were reported to
indicate whether each parameter was statistically significant
in predicting Dmin.
3. RESULTS
3.A. Validation of DIR (inhale 4DCT-exhale 4DCT)
Table II summarizes the uncertainty of the two DIR
methods using the overall TRE as well as DSC for the tumor
contour propagation. The average TRE for the Hybrid method
is 1.2±1.0 mm compared to 2.8±1.6 mm using 
(p= 0.002). The intraobserver variability was within the voxel
size of the images.13 The DSC was on average increased by
0.13 using Hybrid compared to  (p= 0.002); however,
the range of improvement was up to 0.33. The Euclidean
distance between the inhale and exhale tumor (GTV) COG is
also shown in Table II. On average, the COG motion of the
GTV between inhale and exhale was 4.9 mm. The average
residual error in predicting the COG of the GTV on the exhale
image, when using DIR to map the contour, was 2.9 mm using
 and reduced to 0.9 mm using the Hybrid registrations
(p< 0.0005).
3.B. Static dose—Impact of DIR-based contour
mapping on single state dose assessment
In the first experiment, the DIR algorithms were used to
map the GTV contour from the inhale CT to the exhale CT
where the planning dose grid is available from the TPS, as well
as the actual GTV contour. To understand how uncertainties
in DIR algorithms lead to differences in Dmin, the geometric
deviation from the original exhale GTV contour (the planning
GTV) measured by the DSC, a surface distance (based
on Hausdorff distance), DIR-mapped exhale tumor volume
differences, and DHI of the plan was reported in Table III.
The Dmin difference between the two DIR algorithm was
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T II. TRE, GTV COG error, and Dice using  and Hybrid DIR methods for inhale to exhale CT
registrations. N is the number of landmarks for TRE calculations in both lungs.
TRE (mm) GTV COG error (mm) Dice index for tumor
Patient No.  Hybrid N No. registration  Hybrid  Hybrid
1 1.8 ± 1.1 0.8 ± 0.4 63 3.9 1.7 1.0 0.82 0.82
2 2.7 ± 1.3 1.0 ± 0.6 63 7.9 4.3 0.7 0.72 0.88
3 3.2 ± 2.6 1.5 ± 1.7 68 5.4 2.5 0.8 0.87 0.95
4 3.9 ± 3.5 1.5 ± 1.6 63 2.9 3.3 0.6 0.69 0.87
5 2.6 ± 1.7 1.1 ± 1.2 107 5.1 0.6 0.2 0.92 0.95
6 2.6 ± 1.6 0.8 ± 0.4 59 0.6 5.9 0.8 0.45 0.78
7 3.2 ± 1.8 1.7 ± 1.1 61 7.3 2.7 1.7 0.82 0.85
8 2.9 ± 1.4 1.2 ± 1.2 59 8.9 3.1 0.7 0.82 0.91
9,1 2.4 ± 1.3 1.0 ± 0.5 58 3.5 2.4 0.3 0.81 0.92
9,2 N/A N/A N/A 2.5 2.6 2.3 0.57 0.74
10,1 2.5 ± 1.0 1.3 ± 1.2 59 0.9 4.5 0.4 0.36 0.78
10,2 N/A N/A N/A 9.9 1.4 1.2 0.86 0.85
Average 2.8 ± 1.6 1.2 ± 1.0 66 4.9 2.9 0.9 0.73 0.86
significantly different (p= 0.05). The largest Dmin differences
were present in patients 3 and 6 with over 3 Gy differences.
Both patients had high DHI indicating high dose heterogeneity
within the PTV which increases the chance of sensitivity of
Dmin to geometric errors measured by DSC and volume
differences. Patient 3 had a substantial (8.4 cm3) change in the
GTV volume manually contoured on the inhale and exhale
4DCT. Linear regression analysis showed that DHI, volume,
DSC, and surface distance differences could predict Dmin
differences with adjusted R2 = 0.81 and p-values of 0.424,
0.003, 0.007, and 0.806 for each parameter, respectively.
The analysis indicates that the selected parameters were
able to describe 81% of the variations in Dmin differences.
Although, in this experiment, DHI and surface distance
differences did not statistically significantly contribute in
predicting Dmin differences possibly due to small number of
patients. Nevertheless, summarizing the relationship between
these parameters and Dmin in practical ranges shows
promise in identifying the potentially significant Dmin
differences. As shown in Table III, over 50% (n = 10) of
the patients with more than 1 Gy difference exhibited at
least three of the following three characteristics: DHI > 15,
volume differences > 5%, DSC differences > 0.08, and surface
distance differences > 1.5 mm.
3.C. Predicted dose—Impact of DIR-based dose
accumulation over a breathing cycle
The differences between the predicted doses (the DIR-
based accumulated dose using the breathing motion modeled
from 4DCT) using the DIR algorithms are presented in the
far right column of Table III. The Dmin differences between
the DIR algorithms were approaching significant (p= 0.08)
with larger than 1 Gy in patient 3 only. Linear regression
model revealed that DHI, volume, DSC, and surface distance
differences were 55% (R2 = 0.55) predictor of variations in
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1 14.2 0.4 (5%) 0.0 0.01 1.1 1.0 0.1 0.2
2 17.4 0.1 (2%) 0.9 −0.16 0.8 0.0 0.8 0.4
3 27.5 8.4 (19%) 3.0 −0.08 3.3 0.1 3.2 1.1
4 13.0 0.0 (1%) 2.5 −0.18 0.9 0.3 0.6 0.5
5 10.6 0.2 (6%) 0.7 −0.03 0.3 0.3 0.0 0.1
6 19.9 0.4 (8%) 2.8 −0.33 1.8 1.2 3.0 0.4
7 21.4 0.2 (1%) 2.1 −0.03 1.9 1.8 0.1 0.8
8 18.5 0.8 (3%) 1.5 −0.09 3.3 2.1 1.2 0.6
9,1 19.6 0.2 (4%) 0.0 −0.10 1.0 0.1 0.9 0.8
9,2 16.7 0.1 (5%) −1.5 −0.17 2.5 0.7 1.8 0.7
10,1 23.3 0.0 (1%) 0.9 −0.42 0.3 1.2 1.5 0.5
10,2 11.8 0.4 (6%) −0.3 0.01 2.0 1.3 0.7 0.3
Average 17.8 0.9 (N/A) 1.1 −0.13 1.6 0.8 1.2 0.5
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Dmin difference with p-values of 0.009, 0.885, 0.229, and
0.805, respectively. Despite the subtlety of the predicted
dose differences, the results of Table III show that when all
of the three criteria related to the plan and DIR uncertainty
(DHI > 15, volume differences > 5%, DSC differences > 0.08,
and surface distance differences > 1.5 mm) are met, it is
still expected to encounter over 1 Gy in the predicted
Dmin difference. Previously, Rosu et al.22 investigated the
magnitude of changes over a breathing cycle. They found that
the largest differences in the dose due to breathing motion
from inhale to exhale did not exceed 2% in the point dose
and were limited to <0.5% using various clinical metrics. In
the current study, the breathing motion was linearly modeled
using two extreme phases of inhale and exhale with the help of
DIR. The dose was accumulated in six weighted increments,
which led to less pronounced effect of the extreme phases,
and thus, Dmin differences were subtle compared to the static
dose where only the variations on exhale dose were examined.
3.D. Accumulated dose—Impact of DIR-based dose
accumulation over treatment fractions
In the last experiment, the total accumulated dose (the
DIR-based accumulated dose that accounts for residual
uncertainties at treatment delivery and the breathing motion
modeled from 4DCBCT just prior to treatment delivery) was
calculated using both DIR methods. The differences in Dmin
in the GTV as well as DSC, surface distance, and DIR-mapped
GTV volume difference statistics were obtained for each
tumor in each patient. Adjusted R2 value of 0.53 with p-values
of 0.175, 0.988, 0.122, and 0.028 was obtained using a linear
regression model for DHI, volume, DSC, and surface distance
differences in predicting Dmin differences. Table IV shows
that patients 2, 3, and 7 had greater than 2 Gy differences in
Dmin. For patients 3 and 7, DSC, surface distance differences,
DHI, and tumor volumes were over 0.08, 1.5 mm, 20, and
27 cm3, respectively. Dmin differences between the two
DIR algorithms were not statistically significant (p= 0.27).
Dosimetric uncertainties due to geometric differences in DIR
algorithms can be more amplified when the tumor volume is
large and DHI is high (more heterogeneity in the plan). For
patient 2, although the tumor volume and DHI were lower
compared to previous patients, the dosimetric difference was
substantial due to high DSC difference. For the remaining
patients, one (or more) of the four parameters (DSC, surface
distance, volume, and DHI) was too small to produce any
substantial difference in Dmin in the tumor. The result
of Table IV indicates that for tumor volumes > 25 cm3,
when the DHI > 20 reductions of DIR uncertainty (i.e., DSC
differences > 0.08 and surface distance difference > 1.5 mm)
may result in Dmin difference of more than 1 Gy in the
accumulated dose assessment.
4. DISCUSSION
This study investigated the impact of uncertainties in
DIRs on a clinical decision-making dosimetric parameter
in lung SBRT. Such information is important as in the
field of radiation oncology, the utilization of DIR increases.
Four-dimensional planning has been shown to provide better
prediction of dose distribution than the conventional 3D
planning.9 However, it is important to understand how the
DIR uncertainty impacts the dose accumulation so that the
uncertainty associated with the DIR-based dose accumulation
metrics can be understood.
The relationship between the uncertainties in the dose
parameter (Dmin) and the combinational effect of other
factors including DSC, DHI, and GTV volume aid in the
generation of guidelines for which the uncertainties of DIR
may lead to clinically relevant dosimetric uncertainties. This
is consistent with what Hardcastle et al.12 concluded: the
larger the spatial error in high gradient regions, the larger the
dosimetric uncertainty. In addition, this study is also consistent
with the study by Yu et al.,20 which showed that increased DIR
uncertainty can lead to more substantial dose discrepancies.
In the current study, the quantitative measurement of DIR
uncertainty (DSC and surface distance) when combined with
T IV. The differences between final accumulated doses using  and Hybrid methods. In DSC and surface distance difference, values in brackets show
the worst and the best performance cases of the Hybrid compared to , respectively.
Patient No. DHI
% of DIR-mapped GTV volume
difference (–Hybrid)
Surface distance difference (mm)
(–Hybrid) Dice difference (–Hybrid)
Dmin difference (Gy)
(–Hybrid)
1 14.2 28.4 ± 10.0 (11.1,37.6) −0.4 ± 0.3 (−0.5,0.7) 0.05 ± −0.01 (0.12,−0.05) 0.0
2 17.4 23.8 ± 4.0 (16.8,27.1) 2.1 ± 0.9 (1.0,5.2) −0.08 ± 0.04 (0.01,−0.17) 2.1
3 27.5 20.1 ± 4.1 (15.2,25.1) 3.9 ± −0.1 (2.9,6.5) −0.09 ± 0.01 (−0.06,−0.11) 2.5
4 13.0 26.5 ± 14.6 (5.0,41.7) 1.2 ± 0.5 (0.9,4.5) −0.13 ± 0.06 (0.07,−0.36) 0.3
5 10.6 6.4 ± 4.2 (1.0,14.6) 1.3 ± 0.6 (0.5,3.2) −0.14 ± 0.09 (−0.01,−0.29) 0.2
6 19.9 14.1 ± 8.1 (0.0,26.0) 2.4 ± 0.3 (2.6,5.0) −0.18 ± 0.03 (−0.06,−0.27) 0.1
7 21.4 9.5 ± 4.2 (4.7,14.3) 1.9 ± 0.2 (2.3,4.0) −0.08 ± 0.00 (−0.02,−0.14) 2.2
8 18.5 4.6 ± 4.5 (0.5,13.2) 0.5 ± 0.9 (−0.7,2.6) −0.05 ± 0.06 (0.01,−0.11) 0.5
9,1 19.6 11.8 ± 9.7 (0.8,30.8) 0.8 ± 0.1 (0.7,1.7) −0.13 ± 0.06 (0.01,−0.33) 0.5
9,2 16.7 2.1 ± 1.2 (0.3,3.8) 0.1 ± 0.1 (−0.4,4.7) −0.01 ± 0.00 (0.10,−0.19) 0.4
10,1 23.3 25.4 ± 6.4 (15.2,33.1) 0.4 ± 0.4 (0.1,1.7) −0.20 ± 0.08 (0.01,−0.40) 0.2
10,2 11.8 15.2 ± 9.3 (2.4,31.7) 1.2 ± 0.2 (0.9,4.4) −0.02 ± 0.03 (0.02,−0.10) 0.3
Average 17.8 28.4 ± 10.0 (11.1,37.6) 1.3 ± 0.4 (0.8,3.7) −0.1 ± −0.04 (0.01, −0.24) 0.8
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other patient-specific properties such as tumor volume and
planning heterogeneity (as an indicative of dose gradient) was
shown to be an important indication of dosimetric uncertainty.
Deformable image registration plays a significant role in
dose accumulation applications. In this study, the impact of the
accuracy of DIR was investigated on the static, predicted, and
total accumulated dose. Depending on the heterogeneity of
the radiation plan in the tumor, a tumor volume change of 19%
(between inhale and exhale), a 0.08 difference in DSC, and
a minimum of 1.5 mm difference in surface distance (when
mapping a GTV contour onto an alternative static plan) could
affect Dmin by over 3 Gy (patient 3). The biomechanical
based DIR () did not apply any boundary conditions
to the GTV directly, so the change in the GTV volume
(due to variable representation of the tumor on inhale and
exhale 4DCT) was not modeled, leading to a remarkable
DSC and surface distance discrepancy for this patient. Large
discrepancy in tumor volume results in a greater possibility
of covering different doses within a highly heterogeneous
plan (manifested by DHI). When the DIR results were
used through the breathing motion model to calculate the
predicted dose, the dosimetric differences were reduced to 1
Gy (Table III), due to the decrease in the weight of the dose
from one particular breathing position. Summation of the dose
over the course of treatment using different DIR algorithms
involved more complex geometric variations. These variations
measured by DSC, surface distance, and percent of volume
difference statistics combined with other relevant factors (dose
heterogeneity of the plan and the tumor volume) resulted in
up to 2.5 Gy differences in the minimum dose delivered
to 0.5 cm3 volume (Dmin) of the tumor. Such dosimetric
discrepancies may have clinical significance.
Clinical implications of DIR-based dose accumulation
outcomes should be interpreted in the context of the geometric
uncertainties associated with the DIR algorithm. These results
suggest that the uncertainty in Dmin when using DIR-based
dose accumulation may be greater than 1 Gy if the DIR-based
accumulation has the uncertainties of 1.6 mm and if three or
more of the following criteria are met: (1) DHI of the plan
is larger than 15, (2) and (3) DIR-based contour mapping
leads to a DSC and surface distance differences in the tumor
exceeding 0.08 and 1.5 mm, respectively, or (4) tumor volume
difference is larger than 5%. The linear regression analysis
showed the importance of each or a combination of these
parameters in a specific dose scenario. By increasing the
number of patients, it would be expected to observe better
correlation between the uncertainty of Dmin and possibly all
four criteria listed above. In the current preliminary study, it
was found that in presence of these criteria, the likelihood
of a greater than 1 Gy uncertainty in Dmin is 50% when
assessing the static dose on a single breathing phase, 10% for
the predicted dose, and 30% for the accumulated dose for a
SBRT treatment.
Despite the lack of a ground truth accuracy measure for
DIR application in clinical images, geometric and dosimetric
investigations as performed in the current study can help us
to move toward more reliable estimates of the true accuracy.
Landmark- and surface-based techniques to assess accuracy,
as were used in this study, are the only component of the
process to fully understand the accuracy, reliability, and
behavior that are necessary prior to the clinical use of
any DIR algorithm. The development and implications of
additional voxelwise methods of validating DIR algorithms,
such as Jacobians, unbalanced energy (UE), and IC are under
investigation for clinical usage.21 Furthermore, correlating
the dosimetric impact of DIR uncertainties will inform
clinicians of the clinical importance of the use of DIR (i.e.,
Dmin or similar planning parameters) compared to geometric
measures, such as TRE.
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